Back to Annual Meeting Page		American Public Health Association 133rd Annual Meeting & Exposition December 10-14, 2005 Philadelphia, PA

Abstract #108451

Jennifer L. St. Sauver, PhD¹, Debra J. Jacobson, MS², Michaela E. McGree, BS², Michael M. Lieber, MD³, and Steven J. Jacobsen, MD, PhD⁴. (1) Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, (2) Department of Health Sciences Research, Division of Biostatistics, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, (3) Department of Urology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, (4) Health Sciences Research, Division of Epidemiology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, 507-284-5544, jacobsen@mayo.edu

Background: Benign prostatic hyperplasia (BPH) causes substantial morbidity among aging men. The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with a decreased incidence of prostate cancer and because the underlying mechanism might affect BPH, we hypothesized that NSAID users would be at lower risk of BPH as compared to non-NSAID users. Methods: In 1990, 2115 Caucasian men, randomly selected from the Olmsted County, MN population (55% participation), completed validated questionnaires during a home visit by a study assistant. A random subset of 475 (22%) men also agreed to participate in a clinical evaluation that included transrectal ultrasonography, and assessement of serum PSA levels and peak urinary flow rates. Examinations and questionnaires were then repeated biennially through 2002. Age-adjusted Cox proportional hazard models were used to estimate associations between baseline daily NSAID use and onset of BPH measures. BPH measures included development of moderate/severe urinary symptoms (American Urologic Association Symptom Index score >7), a low maximum urinary flow rate (<12 mL/s), a prostate volume >30 mL, or a prostate serum antigen (PSA) level >1.4 ng/mL. Results: After adjusting for age, NSAID use was inversely associated with onset of moderate/severe urinary symptoms (HR=0.74, 95% CI=0.65-0.84) in this population. NSAID use was also inversely associated with onset of a low maximum flow rate (HR=0.52, 95% CI=0.44-0.62), increased prostate volume (HR=0.55, 95% CI=0.42-0.71), and elevated serum PSA level (HR=0.52, 95% CI=0.40-0.68). Conclusions: These data suggest that NSAID use may prevent, delay or retard neoplastic processes in the prostate.

Learning Objectives: At the conclusion of the session, the participant (learner) in this session will be able to

• Understand the methods used to determine the association between NSAID use and benign prostatic hyperplasia (BPH)
• Understand the inverse association between NSAID use and measures of BPH
• Understand how these data may be relevant among aging men

Keywords: Chronic Diseases, Elderly

Presenting author's disclosure statement:

I wish to disclose that I have NO financial interests or other relationship with the manufactures of commercial products, suppliers of commercial services or commercial supporters.